Abstract
Q: What Alzheimer’s related studies are you involved in currently at the Farber Institute for Neurosciences?
Dr. Rovner: We are evaluating three exciting new disease-modifying drug treatments that may slow down the course of Alzheimer’s disease. I am also a Principal Investigator of Jefferson’s Center for Excellence in Neurodegenerative Diseases funded by the Pennsylvania Department of Health Tobacco Settlement grant. We are testing innovative screening methods to identify dementia in community-based agencies serving older adults, as well as testing in-home skills training services to delay nursing home placement and reduce stress for a racially diverse group of family caregivers. This latter study is being conducted at the Center for Applied Research on Aging and Health, by Principal Investigator Laura N. Gitlin, PhD.
Recommended Citation
(2007)
"Speaking with Barry Rovner, MD,"
CenterPieces: Vol. 2:
Iss.
1, Article 3.
Available at:
https://jdc.jefferson.edu/centerpieces/vol2/iss1/3